NEWTON study: an interim assessment on asthma control in Europe

<bold>OBJECTIVES:</bold> To provide an interim analysis of asthma control level in the NEWTON population assessed with the 5-item Asthma Control Questionnaire (ACQ-5, scores: 0 [totally controlled], 6 [extremely poorly controlled]) after 3 and 6 months from starting the treatment with beclometasone dipropionate/formoterol fumarate (BDP/F) 100/6 µg dry powder inhaler via NEXThaler®. <bold>METHODS:</bold> NEWTON is a multinational (DE, ES, FR, HU, IT, RO), 6-month observational study aimed to estimate the proportion of patients improving their asthma control (with ACQ-5 score) in 650 not adequately controlled asthmatics receiving extrafine BDP/FF 100/6 µg via NEXThaler® as both maintenance and as maintenance and reliever therapy (MART). <bold>RESULTS:</bold> In total 345 patients were evaluated for this analysis. Of these 345 patients, 68.4% received MART and 31.6% maintenance treatment only. Respectively, 328 and 247 patients completed the ACQ-5 at 3 and 6-month visits. Improvement of asthma control was reached in 62.8% (n=206) and 69.2% (n=171) of patients after 3 and 6 months of treatment, respectively. After 6 months, 74.5% (n=184) of the patients achieved a minimal clinically important improvement in ACQ-5 score. <bold>CONCLUSIONS:</bold> These results show a significant improvement in the control of asthma symptoms after 3 and 6 months of treatment with extrafine BDP/FF 100/6 µg via NEXThaler®. <fig><object-id>erj;64/suppl_68/PA4500/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>